3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
238
Carcinoma, Non-Small-Cell Lung
205
Prostatic Neoplasms
137
Lung Neoplasms
96
Stomach Neoplasms
85
Head and Neck Neoplasms
58
Squamous Cell Carcinoma of Head and Neck
57
Neoplasms
42
Neoplasm Metastasis
39
Esophageal Neoplasms
36
Ovarian Neoplasms
29
Pancreatic Neoplasms
27
Sarcoma
19
Urinary Bladder Neoplasms
18
Adenocarcinoma of Lung
18
Carcinoma, Squamous Cell
17
Triple Negative Breast Neoplasms
15
Nasopharyngeal Carcinoma
14
Adenocarcinoma
14
Carcinoma, Ovarian Epithelial
13
Adenocarcinoma Of Esophagus
13
Recurrence
12
Inflammatory Breast Neoplasms
10
Carcinoma, Transitional Cell
10
Breast Neoplasms, Male
10
Esophageal Squamous Cell Carcinoma
9
Laryngeal Neoplasms
8
Uterine Cervical Neoplasms
7
Nasopharyngeal Neoplasms
7
Leiomyosarcoma
7
Interventions
cabazitaxel
3
Trastuzumab
3
Cyclophosphamide
2
Cetuximab
2
Carboplatin
2
Aspirin
2
ribociclib
1
pertuzumab
1
eribulin
1
Thiotepa
1
Taxes
1
Stem Cell Transplantation
1
Propofol
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liquid Biopsy
1
Letrozole
1
Ipilimumab
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Gemcitabine
1
Fulvestrant
1
Epirubicin
1
Docetaxel
1
Denosumab
1
Circulating Tumor DNA
1
Cell-Free Nucleic Acids
1
CA-72-4 antigen
1
CA-19-9 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplastic Cells, Circulating
×
Docetaxel
×
Clear all
NCT03101046
2022-02-10
TACTIK
UNICANCER
Phase 2
Completed
40 enrolled